Research Topics
| WILLIAM BARRY WHITESummaryAffiliation: University of Connecticut Health Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Pharmacologic agents in the management of hypertension--nisoldipine coat-coreWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 9:259-66. 2007..Thus, results of more than a decade of clinical trial data support the use of nisoldipine CC as once-daily therapy for the treatment of hypertension...
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbiditiesWilliam B White
University of Connecticut School of Medicine, Farmington, 06030 3940, USA
Am Heart J 164:14-20. 2012..The CARES trial will define the CV safety profile of febuxostat and allopurinol in gout patients at high risk for CV events...- Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?William B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06032 3940, USA
Curr Hypertens Rep 14:366-73. 2012..In this review, we summarize the clinical importance of ABPM and discuss the current guidelines for establishing the diagnosis of hypertension... - Importance of blood pressure control over a 24-hour periodWilliam B White
Department of Medince, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Manag Care Pharm 13:34-9. 2007..Of interest is that cardiovascular (CV) events occur more frequently in the early morning period, the time when BP and heart rate rise steeply... - Clinical assessment of early morning blood pressure in patients with hypertensionWilliam B White
Division of Hypertension and Clinical Pharmacology, The Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, CT 06030 3940, USA
Prev Cardiol 10:210-4. 2007..Given the association between early morning BP and cardiovascular risk, future clinical trials should focus on the efficacy of antihypertensive drugs during this important period of risk... - Cardiovascular effects of the selective cyclooxygenase-2 inhibitorsWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030 3940, USA
Subcell Biochem 42:145-58. 2007.... - Cardiovascular risk, hypertension, and NSAIDsWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
Curr Rheumatol Rep 9:36-43. 2007.... - Cardiovascular effects of the cyclooxygenase inhibitorsWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030-3940, USA
Hypertension 49:408-18. 2007 - Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatmentWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 9:25-30. 2007..Evidence is mounting from studies that support the use of ambulatory BP monitoring in patients with resistant hypertension at the time of diagnosis and following clinically guided therapy... - Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trialsWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
Am J Cardiol 99:91-8. 2007..In conclusion, these analyses failed to demonstrate an increased CV risk with celecoxib relative to placebo and demonstrated a comparable rate of CV events with celecoxib treatment compared with nonselective NSAIDs... - Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertensionWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 8:626-33. 2006..These data support using a higher dose of a thiazide diuretic (25 mg) with a long-acting angiotensin receptor blocker as a useful strategy for improving hypertension control... - Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertensionWilliam B White
Division of Hypertension and Clinical Pharmacology, The Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
Hypertension 48:246-53. 2006..These characteristics may lead to a new benefit for this novel hormone therapy in postmenopausal women with hypertension... - Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care settingWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
Am Heart J 151:176-84. 2006..Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial... - Acute pain in the tip of the index fingerWilliam B White
Pat and Jim Calhoun Cardiology Center, Division of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030-3940, USA
Am J Med 118:1223-4. 2005 - Smoking-related morbidity and mortality in the cardiovascular settingWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Prev Cardiol 10:1-4. 2007..These latest findings should stimulate efforts of health care workers to become more aggressive toward cessation of smoking in our practices... - Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertensionWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Circulation 112:1979-84. 2005..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)... - Update on the drug treatment of hypertension in patients with cardiovascular diseaseWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Center of Cardiology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Am J Med 118:695-705. 2005.... - Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 TrialWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Blood Press Monit 10:157-63. 2005.... - Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an updateWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 9:876-82. 2007..Clinical trial data demonstrate that the effectiveness of RAS blockers is enhanced by maximizing the daily dose and combining these medications with thiazide diuretics... - Cardiovascular risk, hypertension, and NSAIDsWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA
Curr Pain Headache Rep 11:428-35. 2007.... - Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trialWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
Blood Press Monit 13:21-7. 2008..Both studies support the strategy of using angiotensin receptor blockers with a higher dose of a thazide diuretic (25 mg) for enhancing the control of hypertension... - A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorderWilliam B White
Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, 06030 3940, USA
Am Heart J 163:27-32. 2012.... 
Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older peopleWilliam B White
Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 3940, USA
Circulation 124:2312-9. 2011..Little is known about the importance of BP on the progression of microvascular disease of the brain, which has been associated with functional decline in mobility and cognition in older people...- EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wiWilliam B White
University of Connecticut School of Medicine, Farmington, 06030 3940, USA
Am Heart J 162:620-626.e1. 2011..5% for the true HR. Study progress: More than 2,000 ACS patients were randomized as of June 2011. EXAMINE will define the CV safety profile of this dipeptidyl peptidase 4 inhibitor in patients at high risk for CV events... - Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patientsWilliam B White
Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 13:506-16. 2011..The safety and tolerability profile of aliskiren in combination with the ARBs valsartan or losartan, or diuretic, is similar to aliskiren, ARBs, or diuretics alone... - Effects of naproxcinod on blood pressure in patients with osteoarthritisWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
Am J Cardiol 107:1338-45. 2011.... - Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionWilliam B White
Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
Hypertension 57:413-20. 2011..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class... - Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertensionWilliam B White
Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 12:765-75. 2010..At the registered doses of 150 mg and 300 mg daily, aliskiren has safety and tolerability profiles similar to placebo, other RAS blockers, and diuretics. Cough rates are lower with aliskiren compared with ACE inhibitors... - Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertensionWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, 06030, USA
Blood Press Monit 15:205-12. 2010..This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension... - Defining the problem of treating the patient with hypertension and arthritis painWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Am J Med 122:S3-9. 2009.... - Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertensionW B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030, USA
J Hum Hypertens 23:817-25. 2009..The magnitude of the BP-lowering effect provides support for the use of angiotensin receptor blockers with higher doses of a thiazide diuretic (25 mg) to improve hypertension control... - Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson diseaseWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
Hypertension 52:587-93. 2008..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet... - Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a dayWilliam B White
University of Connecticut School of Medicine, Farmington, Connecticut 06030, USA
Am J Med 121:S2-7. 2008.... - Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
J Clin Hypertens (Greenwich) 10:450-8. 2008..This study suggests that in the management of hypertension, utilizing an angiotensin receptor blocker/diuretic combination was more effective in lowering BP and achieving BP goals when compared with increasing the dose of the diuretic... - Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trialW B White
Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Hum Hypertens 22:559-68. 2008..In conclusion, based on its efficacy and tolerability profile the combination of ramipril and HCT was shown to be effective therapy for the treatment of stage 2 hypertension... - Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertensionWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Blood Press Monit 13:123-9. 2008..Recent data and treatment guidelines support the use of a combination strategy as 'initial' antihypertensive therapy in high-risk patients with stage 2 hypertension... - Treatment of benign prostatic hyperplasia in hypertensive menWilliam B White
Section of Hypertension and Clinical Pharmacology, Center for Cardiology and Cardiovascular Biology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 7:212-7. 2005.... - Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure productWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030 3940, USA
Am Heart J 148:628-34. 2004..Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early morning period, a time when both morbid and mortal cardiovascular events are increased compared to other times of the day... - Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritisWilliam B White
Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
Am J Ther 11:244-50. 2004.... - Systolic versus diastolic blood pressure versus pulse pressureWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
Curr Cardiol Rep 4:463-7. 2002..At the present time, outcomes data have not been well established for reductions in pulse pressure in older patients with hypertension... - Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitorsWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Hypertension 39:929-34. 2002..The placebo-subtracted changes observed in 24-hour BP (1.6/1.2 mm Hg) are less than what has been reported for nonselective nonsteroidal anti-inflammatory agents in ACE inhibitor-treated patients... - Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertensionWilliam B White
Section of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmngton Avenue, Farmington, CT 06032, USA
Am J Hypertens 16:739-45. 2003.... - Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxibWilliam B White
Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Am J Cardiol 92:411-8. 2003..These comparative analyses demonstrate no evidence of increased risk of cardiovascular thrombotic events associated with celecoxib compared with either conventional NSAIDs or placebo... - Clinical utility of ambulatory blood pressure: perspectives for national insurance coverageWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Blood Press Monit 7:27-31. 2002.... - Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertensionWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Am J Cardiol 92:38-42. 2003..The top effective dose in stage 1 to 3 hypertension based on clinic and ambulatory BP was 100 mg once daily. The incidence of elevated serum potassium levels was not increased across doses of eplerenone in this study... - Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritisWilliam B White
Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
Am J Cardiol 104:840-5. 2009..04), naproxcinod 375 mg (14%, p = 0.055), and placebo (15.6%, p = 0.155). In conclusion, naproxcinod did not induce elevations of BP seen with naproxen, and it had similar effects on BP to that of placebo in patients with osteoarthritis... - Clinical trial experience around the globe: focus on calcium-channel blockersWilliam B White
Department of Medicine, Division of Hypertension and Clinical Pharmacology, Clinical Trials Unit, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Clin Cardiol 26:II7-11. 2003..The evidence shows that calcium antagonists remain an important part of hypertension management, including in those individuals at risk of cardiac and cerebrovascular events... - Chronopharmacology of cardiovascular therapyWilliam B White
Section of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, Farmington 06030-3940, USA
Blood Press Monit 7:199-207. 2002 - Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arisingWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030 3940, USA
Am Heart J 144:657-65. 2002..Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early-morning period, a time when both morbid and mortal cardiovascular events are increased compared with other times of the day... - Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenacWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Am J Cardiol 89:425-30. 2002.... - Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertensionW B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, USA
Am J Hypertens 14:1248-55. 2001..Although the drug has a relatively short plasma half-life of 5 to 9 h, clinical studies have suggested that its antihypertensive effect persists for 24 h... - The evaluation of antihypertensive therapy using 24-h ambulatory monitoring technologyW B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Blood Press Monit 5:S13-7. 2000..In this article, an overview of the utility of ambulatory blood pressure monitoring in clinical trials is provided, with specific examples that use data from recent studies of the newer compounds that block the renin-angiotensin system... - Circadian variation of blood pressure and the assessment of antihypertensive therapyW B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06032 3940, USA
Blood Press Monit 4:S3-6. 1999..In this review, we evaluate new data on the clinical impact of cardiovascular chronotherapy and the importance of timing of dosing on pharmacodynamics... - How well does ambulatory blood pressure predict target-organ disease and clinical outcome in patients with hypertension?W B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030, USA
Blood Press Monit 4:S17-21. 1999..These data all support the desirability of increased utilization of 24 h ambulatory blood pressure monitoring in clinical trials of antihypertensive drugs and in the management of hypertensive patients in clinical practice... - Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning periodWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06032, USA
Am J Hypertens 17:347-53. 2004.... - Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adultsW B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, Farmington, Connecticut 06030 3940, USA
Blood Press Monit 6:107-10. 2001..The objective of this study was to assess the accuracy of the HEM-907, a new semi-automatic, non-invasive, oscillometric blood pressure monitoring device specifically designed to be used in the clinic or physician's office setting... - Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rateW B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Blood Press Monit 6:63-72. 2001.... - Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapyW B White
University of Connecticut School of Medicine, Farmington, USA
Am J Hypertens 14:1239-47. 2001.... - Ambulatory blood pressure monitoring: dippers compared with non-dippersW B White
University of Connecticut Science Center, Farmington, Connecticut, USA
Blood Press Monit 5:S17-23. 2000..In the near future, the benefits of a chronotherapeutic approach to the management of hypertension should be elucidated by large-scale outcome studies... - Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida
Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
Mov Disord 21:1716-21. 2006..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction... - Comparative effects of telmisartan in the treatment of hypertensionWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030-3940, USA
J Clin Hypertens (Greenwich) 4:20-5. 2002.... - Relevance of blood pressure variation in the circadian onset of cardiovascular eventsWilliam B White
University of Connecticut Health Center, Hypertension and Clinical Pharmacology, Farmington, Connecticut 06030, USA
J Hypertens Suppl 21:S9-15. 2003..Direct comparative studies with telmisartan and other angiotensin-II receptor blockers and with amlodipine have shown that telmisartan has a long duration of action and controls blood pressure over the 24-h dosing period... - Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertensionWilliam B White
Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, Conn 06030-3940, USA. wwhite @nso1.uchc.edu
Hypertension 41:1021-6. 2003..Furthermore, eplerenone reduced microalbuminuria to a greater extent than amlodipine in this older patient group... - Sleep-disordered breathing and 24-hour blood pressure pattern among older adultsYohannes W Endeshaw
Division of Geriatrics and Gerontology, Department of Medicine, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30329, USA
J Gerontol A Biol Sci Med Sci 64:280-5. 2009..To examine the association between sleep-disordered breathing (SDB) and 24-hour blood pressure (BP) pattern among community-dwelling older adults... - Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal womenRichard A Preston
Division of Clinical Pharmacology and Pharmacokinetics Clinical Research Center, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
Am J Hypertens 18:797-804. 2005..Because of a significant aldosterone antagonist activity, we studied the effects of DRSP/E2 on serum potassium (K) and blood pressure (BP) in hypertensive postmenopausal women with and without diabetes mellitus... - Evaluation of recent fixed-dose combination therapies in the management of hypertensionApurv Khanna
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Curr Opin Nephrol Hypertens 17:477-83. 2008..This review discusses the drug combinations that have additive effects and those that do not provide additional benefit while increasing the adverse events... - The management of hyperkalemia in patients with cardiovascular diseaseApurv Khanna
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
Am J Med 122:215-21. 2009..Management of hyperkalemia may be improved by identifying the levels of potassium that may potentially induce harm and using appropriate strategies to avert the levels that may be dangerous or life threatening... - COX-2 selective inhibitors and heart healthLee S Simon
University of Connecticut Health Center, Farmington, CT 06030, USA
Postgrad Med 117:7-20. 2005..This review evaluates and differentiates the CV effects of COX-2 selective inhibitors through an assessment of prospective, randomized epidemiologic studies and meta-analyses... - Hypertension in the postpartum woman: clinical update for the hypertension specialistNimrta Ghuman
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
J Clin Hypertens (Greenwich) 11:726-33. 2009..The purpose of this clinical review article is to provide an approach to the management of postpartum hypertension... - The importance of the clinical observer in the development of a white-coat effect in African-American patients with hypertensionPaul T Labinson
Section of Hypertension and Clinical Pharmacology, Center for Cardiology and Cardiovascular Biology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3949, USA
Blood Press Monit 13:139-42. 2008.... - Self-measured home blood pressure in predicting ambulatory hypertensionGeorge A Mansoor
Section of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, Farmington, Connecticut, USA
Am J Hypertens 17:1017-22. 2004..However, some persons with home BP below this cut-off will have ambulatory hypertension. We therefore prospectively study the role of home BP in predicting ambulatory hypertension in persons with stage 1 and borderline hypertension... - Abnormalities in blood pressure regulation in a patient with Parkinson's diseaseJose R Arias-Vera
Section of Hypertension and Vascular Diseases, UCONN Health Center, University of Connecticut School of Medicine, Farmington, Connecticut 06032-3940, USA
Am J Hypertens 16:612-3. 2003 - Drospirenone, a new progestogen, for postmenopausal women with hypertensionMadhavi Mallareddy
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
Drugs Aging 24:453-66. 2007..Thus, drospirenone is a unique progestogen that confers the additional benefit of BP reduction, an effect that could lead to potential benefit with respect to some cardiovascular risk concerns in women taking hormone therapy... - Importance of aggressive blood pressure lowering when it may matter mostWilliam B White
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06032 3940, USA
Am J Cardiol 100:10J-16J. 2007..Studies of this nature can even assess blood pressure control in the early-morning period by sequestering data before and after awakening... - Relevance of blood pressure variation in the circadian onset of cardiovascular eventsWilliam B White
University of Connecticut Health Center, Hypertension and Clinical Pharmacology, Farmington, Connecticut 06030, USA
J Hypertens Suppl 21:S9-15. 2003..Direct comparative studies with telmisartan and other angiotensin-II receptor blockers and with amlodipine have shown that telmisartan has a long duration of action and controls blood pressure over the 24-h dosing period... - Primary hyperaldosteronism associated with hypertensive emergenciesPaul T Labinson
Section of Hypertension, Pat and Jim Calhoun Center for Cardiology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
Am J Hypertens 19:623-7. 2006..The differential diagnosis of hypertensive emergencies should include primary hyperaldosteronism... - Determinants of left atrial size in patients with newly diagnosed untreated hypertensionGeorge A Mansoor
University of Connecticut Health Center, Farmington, Connecticut 06030, USA
Blood Press Monit 8:3-7. 2003..These data demonstrate that body mass index and left ventricular mass were the main correlates of left atrial size in patients with previously untreated stage I-II hypertension... - Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevanceAldo J Peixoto
Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA
Curr Opin Nephrol Hypertens 11:507-16. 2002..To evaluate the current value of ambulatory blood pressure monitoring in patients with chronic renal disease and end-stage renal disease... - Hypertension management: differing points of view: ambulatory blood pressure monitoring for every hypertensive patient: it's about time!: the argument againstWilliam B White
Section of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
J Clin Hypertens (Greenwich) 6:710-3; quiz 714. 2004 - Effects of eplerenone versus losartan in patients with low-renin hypertensionMyron H Weinberger
Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
Am Heart J 150:426-33. 2005..Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension... - Hypertension associated with therapies to treat arthritis and painWilliam B White
Hypertension 44:123-4. 2004 - Sustained antihypertensive activity of telmisartan compared with valsartanYves Lacourciere
Hypertension Research Unit, Centre Hospitalier l Université de Quebec, Ste Foy, Quebec, Canada
Blood Press Monit 9:203-10. 2004..The efficacies of the long half-life telmisartan compared with shorter half-life valsartan in the last 6 h of the dosing interval following active treatment and during 24 h after a missed dose were compared... - Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertensionWilliam B White
J Hypertens 22:2035-6; author reply 2036-8. 2004 - The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitusJames R Sowers
State University of New York, Brooklyn, USA
Arch Intern Med 165:161-8. 2005..However, destabilization of hypertension control occurred to some extent in all 3 treatment groups; this phenomenon was seen more often in patients treated with rofecoxib than with the other therapies... - The use of peridialysis blood pressure and intradialytic blood pressure changes in the prediction of interdialytic blood pressure in haemodialysis patientsRoger B Mendes
GAMEN - Grupo de Assistencia Medica e Nefrologica, Rio de Janeiro, Brazil
Blood Press Monit 8:243-8. 2003..Clinical decisions related to blood pressure management and research design in haemodialysis hypertension should take these factors into account... - An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurementsMichael A Weber
SUNY Downstate Medical School, Brooklyn, NY 11203, USA
J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006..A treatment algorithm based on the angiotensin receptor blocker, telmisartan, was confirmed by the blinded end point of ABPM as an efficacious alternative to other antihypertensive regimens in clinical practice... - Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasiaStephen M Auerbach
California Professional Research, Newport Beach, California 92660, USA
Urology 64:998-1003; discussion 1003-4. 2004..No serious adverse events were reported. CONCLUSIONS: In this study, no evidence was found that coadministered vardenafil and tamsulosin induced clinically significant hypotension in patients with BPH... - Controversies in COX-2 selective inhibitionLee S Simon
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Rheumatol 29:1501-10. 2002 - Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportionWilliam B White
Am J Cardiol 92:1439-41. 2003 - Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicineStephen G Ball
Department of Cardiovascular Medicine, University of Leeds, Leeds, United Kingdom
Am J Cardiol 91:15G-21G. 2003.... - Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialHenry R Black
Rush Medical College of Rush University, Chicago, IL 60612, USA
JAMA 289:2073-82. 2003..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial... - Management of hypertension in patients with enhanced cardiovascular risk. IntroductionWilliam B White
Am J Med 121:S1. 2008 - Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patientsGeorge L Bakris
Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians... - Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritisAndrew Whelton
Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
Am J Cardiol 90:959-63. 2002..7%) compared with the celecoxib group (4.7%) (p <0.05). Thus, in patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy...
Research Grants
- Contingency Management for Initiating Smoking AbstinenceWilliam White; Fiscal Year: 2009..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
- Contingency Management for Initiating Smoking AbstinenceWILLIAM BARRY WHITE; Fiscal Year: 2010..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..